Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28859
U.S. Patent No. 5,885,794 issued March 23, 1999, Cloning and Recombinant Production of Receptor(s) of the Activin/TGF-B Superfamily
U.S. Patent No. 6,162,896 issued December 19, 2000, Recombinant Vertebrate Activin Receptors,
U.S. Application Serial No. 09/742,684, filed December 19, 2000.Cloning and Recombinant Production of Receptor(s) of the Activin/TGF-B Superfamily,
Development of ActRIIa and/or ActRlIb as Human Therapeutics for the Treatment of Muscle Wasting Disorders
IPSCIO Record ID: 7481
Biological Property shall mean any DNA materials, derivatives of such DNA materials, cell lines and peptides containing the DNA materials or derivatives thereof, that are related to the TGF-B Antibody Patent Rights, and to the TGF-B Receptor Patent Rights, respectively.
TGF-B Antibody Patent Rights shall mean the Patent Rights that relate to monoclonal antibodies that bind Transforming Growth Factor ('TGF-B'), specifically TGF-B1 and TGF-B2.
TGF-B Receptor Patent Rights Licensed from MIT shall mean the Patent Rights that relate to TGF-B receptors, including TGF-B type II and TGF-B type III receptors, cDNA of the respective receptors, and methods of use.
IPSCIO Record ID: 28866
Sotatercep tis a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
ACE-536 is an investigational protein therapeutic that increases red blood cell levels by targeting molecules in the TGF-β superfamily being developed ACE-536 to treat anemia in patients with rare blood disorders, including β-Thalassemia and myelodysplastic syndromes .